UY31146A1 - Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene - Google Patents

Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene

Info

Publication number
UY31146A1
UY31146A1 UY31146A UY31146A UY31146A1 UY 31146 A1 UY31146 A1 UY 31146A1 UY 31146 A UY31146 A UY 31146A UY 31146 A UY31146 A UY 31146A UY 31146 A1 UY31146 A1 UY 31146A1
Authority
UY
Uruguay
Prior art keywords
androst
ciano
eno
medication
derived
Prior art date
Application number
UY31146A
Other languages
English (en)
Inventor
Frederik Menges
Jan Huebner
Steffen Borden
Katja Prelle
Sven Ring
Hans Peter Muhn
Rolf Bohlmann
Ulrich Klar
Joachin Kuhnke
T Frenzel
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY31146A1 publication Critical patent/UY31146A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los derivados de 17b-ciano-19-nor-androst-4-eno de la presente invención presentan actividad gestágena. Tienen la fórmula química general 1.
UY31146A 2007-06-12 2008-06-11 Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene UY31146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007027637A DE102007027637A1 (de) 2007-06-12 2007-06-12 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
UY31146A1 true UY31146A1 (es) 2009-01-30

Family

ID=39986163

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31146A UY31146A1 (es) 2007-06-12 2008-06-11 Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene

Country Status (20)

Country Link
US (1) US8207150B2 (es)
EP (1) EP2170925B1 (es)
JP (1) JP2010529153A (es)
KR (1) KR20100028554A (es)
CN (1) CN101679478A (es)
AR (1) AR066971A1 (es)
AU (1) AU2008261278A1 (es)
BR (1) BRPI0813937A2 (es)
CA (1) CA2690959A1 (es)
DE (1) DE102007027637A1 (es)
ES (1) ES2397996T3 (es)
IL (1) IL202359A0 (es)
MX (1) MX2009013629A (es)
PA (1) PA8784401A1 (es)
PE (1) PE20090822A1 (es)
RU (1) RU2010100331A (es)
TW (1) TW200909444A (es)
UY (1) UY31146A1 (es)
WO (1) WO2008151746A2 (es)
ZA (1) ZA201000187B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007027635A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
WO2010066355A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
CN104530165A (zh) * 2014-12-10 2015-04-22 浙江仙琚制药股份有限公司 制备4,9-双烯物的方法
CN105085596A (zh) * 2015-08-18 2015-11-25 湖北竹溪人福药业有限责任公司 一种羧酸***的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043833A (en) * 1961-07-14 1962-07-10 Ormonoterapia Richter Spa 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3579509A (en) * 1965-06-21 1971-05-18 Smith Kline French Lab Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids
GB1089945A (en) * 1965-09-23 1967-11-08 British Drug Houses Ltd Steroidal-6-spirocyclopropyl-4-en-3-ones
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
FR2139708B1 (es) 1971-06-01 1974-08-23 Roussel Uclaf
BE795241A (fr) 1972-02-11 1973-08-09 Schering Ag 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation
DE2456068A1 (de) 1974-11-23 1976-08-12 Schering Ag Verfahren zur herstellung von oestren3,17-dion-derivaten
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
US4252800A (en) * 1979-10-05 1981-02-24 United States Of America 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DD281393A5 (de) * 1984-12-10 1990-08-08 Jenapharm Veb Verfahren zur herstellung von steroid-c-17 beta-carbonitrilen
DD281394A5 (de) * 1984-12-10 1990-08-08 Jenapharm Veb Verfahren zur herstellung von steroid-c-17 alpha-carbonitrilen
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
EP0785211A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Also Published As

Publication number Publication date
IL202359A0 (en) 2010-06-30
PA8784401A1 (es) 2009-01-23
CA2690959A1 (en) 2008-12-18
PE20090822A1 (es) 2009-07-25
US8207150B2 (en) 2012-06-26
TW200909444A (en) 2009-03-01
AR066971A1 (es) 2009-09-23
ZA201000187B (en) 2011-03-30
WO2008151746A2 (de) 2008-12-18
KR20100028554A (ko) 2010-03-12
DE102007027637A1 (de) 2008-12-18
US20090048217A1 (en) 2009-02-19
CN101679478A (zh) 2010-03-24
BRPI0813937A2 (pt) 2014-12-30
AU2008261278A1 (en) 2008-12-18
MX2009013629A (es) 2010-01-20
JP2010529153A (ja) 2010-08-26
EP2170925B1 (de) 2012-10-24
WO2008151746A3 (de) 2009-03-12
EP2170925A2 (de) 2010-04-07
ES2397996T3 (es) 2013-03-13
RU2010100331A (ru) 2011-07-20

Similar Documents

Publication Publication Date Title
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CR11861A (es) Compuestos organicos
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CO7111285A2 (es) Composiciones pesticidas y procesos relacionados con ellas
SV2009003392A (es) Aril pirrolidinas insecticidas
BR112015014562A2 (pt) composições pesticidas e processos com estas relacionados
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
PA8667201A1 (es) Nuevos compuestos farmaceuticos
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
EA200702352A1 (ru) Новые композиции нутрицевтиков
ECSP109968A (es) Depsipéptidos cíclicos
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
UY30451A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroéteres (18-metil-19-nor-20-espirox-4-en-3-onas),ase como preparaciones farmacéuticas que lo contienen.
CO6571898A2 (es) Composición pesticida y su uso
BRPI0916571A2 (pt) composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto
UY31146A1 (es) Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene
CL2008001048A1 (es) Compuestos derivados de heterociclos nitrogenados; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como antibacterianos.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171006